EyePoint Secures $300M Cash Runway into Q4 2027, Phase 3 DURAVYU Trials On Track
EyePoint closed 2025 with $300 million cash and investments, funding operations into Q4 2027 and dosing patients in Phase 3 COMO and CAPRI trials for DURAVYU in DME. LUGANO, LUCIA AMD trials remain on track for mid-2026 readouts; Michael Campbell appointed CCO to lead launch readiness.
1. Financial Position
As of December 31, 2025, EyePoint held over $300 million in cash and investments, providing an operational runway into Q4 2027 and reflecting the completion of a $172.5 million underwritten public offering in October 2025.
2. Wet AMD Phase 3 Progress
Two identical pivotal Phase 3 trials, LUGANO and LUCIA, evaluating DURAVYU for wet AMD have enrolled over 900 patients, received two positive Data Safety Monitoring Committee reviews with no protocol modifications, and anticipate topline data starting mid-2026.
3. DME Phase 3 Progress
EyePoint has dosed the first patients in its pivotal COMO and CAPRI trials for DURAVYU in diabetic macular edema, targeting rapid enrollment of approximately 240 patients per study and expecting topline data in the second half of 2027.
4. Commercial and Patent Developments
Michael Campbell has been appointed Chief Commercial Officer to drive DURAVYU launch strategy; a U.S. patent issued in February 2026 extends insert formulation coverage into 2043, and registration batches have been manufactured to support the planned NDA CMC filing.